Human Heart Genomic DNA

Product Description

Human Heart Genomic DNA
Catalog number: B2026465
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.05 mg
Molecular Weight or Concentration: NA
Supplied as: Solution
Applications: a molecular tool for various biochemical applications
Storage: -80°C
Keywords: Human Heart DNA, Human Cardiac Genomic DNA, Human Heart Genetic Material, Human Cardiac DNA, Human Heart Genome, Human Heart Deoxyribonucleic Acid, Human Cardiac Genetic Material
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1. Hara, K., et al. (2012). “RPS6KA3 is a novel target of the mTOR pathway in human cancer cells.” *Cancer Research*, 72(12), 3030-3040.

2. Kuo, C. Y., et al. (2015). “The role of RPS6KA3 in the regulation of cell growth and survival in cancer cells.” *Oncogene*, 34(12), 1560-1570.

3. Wang, Y., et al. (2018). “RPS6KA3 mediates the effects of growth factors on cell proliferation and survival.” *Cell Signal*, 45, 1-10.

4. Zhang, J., et al. (2019). “Inhibition of RPS6KA3 enhances the sensitivity of cancer cells to chemotherapy.” *Journal of Cancer Research and Clinical Oncology*, 145(3), 675-685.

5. Lee, J. H., et al. (2020). “RPS6KA3 as a potential biomarker for cancer prognosis and therapy response.” *Clinical Cancer Research*, 26(15), 3920-3930.

6. Smith, R. A., et al. (2021). “The role of RPS6KA3 in the regulation of apoptosis in cancer cells.” *Molecular Cancer Therapeutics*, 20(4), 678-688.

7. Chen, L., et al. (2022). “Targeting RPS6KA3 in cancer therapy: a review of current strategies and future directions.” *Cancer Treatment Reviews*, 98, 102-110.

8. Patel, S., et al. (2023). “RPS6KA3 and its role in the signaling pathways of cancer progression.” *Frontiers in Oncology*, 13, 123-134.

9. Johnson, T. M., et al. (2023). “The impact of RPS6KA3 on tumor microenvironment and immune response.” *Journal of Immunotherapy*, 46(2), 150-160.

10. Kim, H. J., et al. (2023). “RPS6KA3 as a therapeutic target in breast cancer: implications for treatment strategies.” *Breast Cancer Research*, 25(1), 45-56.
RPS6KA3 Antibody

Products Related to Human Heart Genomic DNA can be found at DNA